FDA approves OPDIVO QVANTIG for multiple advanced cancer indications including renal cell carcinoma and melanoma
FDA approves subcutaneous nivolumab combination for multiple advanced cancers
This FDA approval document grants authorization for OPDIVO QVANTIG, a subcutaneous combination of nivolumab and hyaluronidase, for specified…
The FDA has approved a new subcutaneous form of nivolumab for several advanced cancers, offering a more convenient treatment option for elig…
Meta-analysis of pucotenlimab shows improved outcomes across multiple solid tumors
New analysis shows pucotenlimab improves outcomes for several solid tumor types
This meta-analysis evaluated pucotenlimab (HX008) in patients with gastric, gastroesophageal junction, triple-negative breast cancer, melano…
A new analysis of pucotenlimab shows significantly improved outcomes versus control for patients with gastric cancer, triple-negative breast…
Envafolimab plus lenvatinib and paclitaxel shows activity in advanced gastric cancer after first-line progression
New Drug Combo Gives Hope for Late-Stage Stomach Cancer
This phase II, single-center, open-label trial evaluated envafolimab combined with lenvatinib and albumin-bound paclitaxel in 30 patients wi…
Imagine a patient who has already tried every standard treatment available.
Research across Cancer
Related studies from across the Cancer family.
Meta-analysis finds sex-based differences in ICI survival benefit for advanced gastroesophageal cancer
Immunotherapy Works Differently for Men and Women with Stomach Cancer
This meta-analysis of 15 RCTs examined immune-checkpoint inhibition for advanced gastroesophageal cancer. It found a significant overall sur…
Men with esophageal cancer gain a clear survival edge from immunotherapy, while women do not, but both sexes benefit similarly in stomach ca…
Case report and literature review on oxaliplatin and tegafur for AEG with intramural metastasis
A rare cancer spread inside the esophagus wall needs careful treatment plans for older adults
This case report and literature review examines a 77-year-old male with adenocarcinoma of the esophagogastric junction and esophageal intram…
A doctor reviewed a rare case where cancer spread inside the esophagus wall. This condition often means the disease is already in the body. …
pCR shows poor surrogacy for OS in neoadjuvant GEA trials overall, but strong for esophageal adenocarcinoma
When a cancer disappears before surgery, does it mean patients live longer? Not always, a major review finds
A meta-analysis of 26 RCTs (n=7452) found pathologic complete response (pCR) was not a valid surrogate for overall survival (OS) in neoadjuv…
For stomach or esophageal cancer, a tumor disappearing before surgery does not always mean patients live longer, a major review finds.